CTOs on the Move

Golden Sap

www.goldensap.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.goldensap.com
  • 8 rang Saint-Jean-Baptiste RR 2
    Sainte-Aurķ©lie, QC CAN G0M 1M0
  • Phone: 860.289.4053

Executives

Name Title Contact Details

Similar Companies

Phlow

Securing our nation’s pharmaceuticals through U.S. Manufacturing.

Clever Leaves

Clever Leaves is a multi-national cannabis company with a mission to operate in compliance with federal and state laws and with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade processing as the cornerstones of its global cannabinoid business. With operations and investments in Canada, Colombia, Germany, Portugal, and the United States, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry`s leading global cannabinoid companies recognized for its principles, people, and performance while fostering a healthier global community.

WN Pharmaceuticals

WN Pharmaceuticals Ltd is a Coquitlam, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HearingLife

HearingLife offers hearing wellness care and hearing aids for people who want to achieve optimal results. For a free hearing assessment call (844) 836-5003.

SAB Biotherapeutics

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovineā„¢ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAbā„¢ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.